Cytokinetics Receives Complete Response Letter From FDA for

Complete Response Letter States that GALACTIC-HF Alone Does not Establish Substantial Evidence of Effectiveness Sufficient for Approval Company Expects to...

Related Keywords

United States ,American ,Ruoxiang Jiang ,Susana Weston ,Shannonm Dunlay ,Margaretm Redfield ,Omecamtiv Mecarbil ,Diane Weiser ,Roberti Blum ,American Heart Association ,Heart Failure Association ,Linkedin ,Twitter ,Company Expects To Request Meeting ,Drug Administration ,Exchange Commission ,Cytokinetics Incorporated Nasdaq ,Youtube ,Corporate Communications ,European Society Of Cardiology ,Facebook ,Circulation Research ,Complete Response Letter States ,Establish Substantial Evidence ,Effectiveness Sufficient ,Request Meeting ,Discuss Potential Next Steps ,Host Conference Call ,Complete Response Letter ,New Drug Application ,Global Approach ,Heart Failure ,Cytokinetic President ,Chief Executive ,Omecamtiv Mecarbil Regulatory Update ,Private Securities Litigation Reform Act ,Safe Harbor ,Vice President ,Circ Heart ,Injury Incidence ,American College ,American Heart Association Task Force ,Task Force ,European Society ,Eur Heart ,Risk Manag Healthc ,Term Trends ,First Hospitalization ,Subsequent Survival Between ,Stroke Statistics ,Report From ,American Heart ,Heart Failure Incidence ,Olmsted County ,Nasdaq Cytk ,Cytokinetics ,Ncorporated ,Cytk ,Biotechnology ,